|
|
|
| Research progress in the eradication of Helicobacter pylori with Vanorazan regimen |
| DU Hongwei1 LI Ting1 ZHANG Aiping1 LIN Yimin2 JIN Zhengxu1▲ ZHANG Dekui2▲#br# |
1.Department of Gastroenterology, Lanzhou Second People’s Hospital, Gansu Province, Lanzhou 730030, China;
2.Department of Gastroenterology, the Second Hospital of Lanzhou University, Gansu Province, Lanzhou 730030, China |
|
|
|
Abstract Helicobacter pylori (Hp) is closely related to chronic gastritis, peptic ulcer, and gastric cancer. The eradication rate of Hp with proton pump inhibitor decreased gradually. Vonoprazan (VPZ) is a new potassium ion competitive acid blocker, which can competitively inhibit the combination of K+ and H+-K+-ATPase to inhibit the acid secretion of gastric parietal cells. There have been a number of international reports on the first-line and second-line treatment regimen containing VPZ for eradicating Hp, which are reviewed in this paper.
|
|
|
|
|
|
[1] Wroblewski LE，Peek RM Jr，Wilson KT. Helicobacter pylori and gastric cancer：factors that modulate disease risk [J]. Clin Microbiol Rev，2010，23（4）：713-739.
[2] Rokkas T，Gisbert JP，Malfertheiner P，et al. Comparative Effectiveness of Multiple Different First-Line Treatment Regimens for Helicobacter pylori Infection：A Network Meta-analysis [J]. Gastroenterology，2021，161（2）：495-507.e4.
[3] Shichijo S，Hirata Y，Niikura R，et al. Vonoprazan versus conventional proton pump inhibitor-based triple therapy as first-line treatment against Helicobacter pylori：A multicenter retrospective study in clinical practice [J]. Dig Dis，2016，17（10）：670-675.
[4] Talebi Bezmin Abadi A，Yamaoka Y. Helicobacter pylori therapy and clinical perspective [J]. Glob Antimicrob Resist，2018，14：111-117.
[5] Zhong Z，Zhang Z，Wang J，et al. A retrospective study of the antibiotic-resistant phenotypes and genotypes of Helicobacter pylori strains in China [J]. Am J Cancer Res，2021，11（10）：5027-5037.
[6] Sue S，Maeda S. Is a Potassium-Competitive Acid Blocker Truly Superior to Proton Pump Inhibitors in Terms of Helicobacter pylori Eradication? [J]. Gut Liver，2021，15（6）：799-810.
[7] Sugimoto M，Hira D，Murata M，et al. Effect of Antibiotic Susceptibility and CYP3A4/5 and CYP2C19 Genotype on the Outcome of Vonoprazan-Containing Helicobacter pylori Eradication Therapy [J]. Antibiotics（Basel），2020，9（10）：645.
[8] Sakurai Y，Shiino M，Okamoto H，et al. Pharmacokinetics and Safety of Triple Therapy with Vonoprazan，Amoxicillin，and Clarithromycin or Metronidazole：A Phase 1，Open-Label，Randomized，Crossover Study [J]. Adv Ther，2016，33（9）：1519-1535.
[9] Hunt RH，Scarpignato C. Potassium-Competitive Acid Blockers （P-CABs）：Are They Finally Ready for Prime Time in Acid-Related Disease? [J]. Clin Transl Gastroenterol，2015，6（10）：e119.
[10] Jenkins H，Sakurai Y，Nishimura A，et al. Randomised clinical trial：safety，tolerability，pharmacokinetics and pharmacodynamics of repeated doses of TAK-438（vonoprazan），a novel potassium-competitive acid blocker，in healthy male subjects [J]. Aliment Pharmacol Ther，2015， 41（7）：636-648.
[11] Huh KY，Chung H，Kim YK，et al. Evaluation of safety and pharmacokinetics of bismuth-containing quadruple therapy with either vonoprazan or lansoprazole for Helicobacter pylori eradication [J]. Br J Clin Pharmacol，2022，88（1）：138-144.
[12] Kagami T，Sahara S，Ichikawa H，et al. Potent acid inhibition by vonoprazan in comparison with esomeprazole，with reference to CYP2C19 genotype [J]. Aliment Pharmacol Ther，2016，43（10）：1048-1059.
[13] Yamasaki H，Kawaguchi N，Nonaka M，et al. In vitro metabolism of TAK-438，vonoprazan fumarate，a novel potassium-competitive acid blocker [J]. Xenobiotica，2017，47（12）：1027-1034.
[14] Mori H，Suzuki H，Omata F，et al. Current status of first- and second-line Helicobacter pylori eradication therapy in the metropolitan area：a multicenter study with a large number of patients [J]. Therap Adv Gastroenterol，2019， 12：1756284819858511.
[15] Murakami K，Sakurai Y，Shiino M，et al. Vonoprazan，a novel potassium-competitive acid blocker，as a component of first-line and second-line triple therapy for Helicobacter pylori eradication：a phase Ⅲ，randomised，double-blind study [J]. Gut，2016，65（9）：1439-1446.
[16] Suzuki S，Gotoda T，Kusano C，et al. The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy [J]. Am J Gastroenterol，2016，111（7）：949-956.
[17] Shinozaki S，Nomoto H，Kondo Y，et al. Comparison of vonoprazan and proton pump inhibitors for eradication of Helicobacter pylori [J]. Kaohsiung J Med Sci，2016，32（5）：255-260.
[18] Maruyama M，Tanaka N，Kubota D，et al. Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-Line Helicobacter pylori Eradication：A Randomized Controlled Trial [J]. Can J Gastroenterol Hepatol，2017，2017：4385161.
[19] Furuta T，Yamade M，Kagami T，et al. Dual Therapy with Vonoprazan and Amoxicillin Is as Effective as Triple Therapy with Vonoprazan，Amoxicillin and Clarithromycin for Eradication of Helicobacter pylori [J]. Digestion，2020，101（6）：743-751.
[20] Mori N，Nishiura Y，Suga D，et al. Second-line triple therapy in failures with vonoprazan -based triple therapy for eradication of Helicobacter pylori [J]. Biomed Rep，2018，9（2）：169-174.
[21] Sakurai K，Suda H，Ido Y，et al. Comparative study：Vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy [J]. World J Gastroenterol，2017，23（4）：668-675.
[22] Sue S，Suzuki N，Shibata W，et al. First-Line Helicobacter pylori Eradication with Vonoprazan，Clarithromycin，and Metronidazole in Patients Allergic to Penicillin [J]. Gastroenterol Res Pract，2017，2017：2019802.
[23] Ono S，Kato M，Nakagawa S，et al. Vonoprazan improves the efficacy of Helicobacter pylori eradication therapy with a regimen consisting of clarithromycin and metronidazole in patients allergic to penicillin [J]. Helicobacter，2017，22（3）：e12374.
[24] Horie R，Handa O，Ando T，et al. Helicobacter pylori eradication therapy outcome according to clarithromycin susceptibility testing in Japan [J]. Helicobacter，2020，25（4）：e12698.
[25] Sue S，Kuwashima H，Iwata Y，et al. The Superiority of Vonoprazan-based First-line Triple Therapy with Clarithromycin：A Prospective Multi-center Cohort Study on Helicobacter pylori Eradication [J]. Intern Med，2017，56（11）：1277-1285.
[26] Gunaratne AW，Hamblin H，Clancy A，et al. Combinations of antibiotics and vonoprazan for the treatment of Helicobacter pylori infections-Exploratory study [J]. Helicobacter，2021，26（5）：e12830. |
|
|
|
